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Abstract
Objective: A higher incidence of urinary tract transitional cell carcinoma 
(TCC) has been reported in both long-term hemodialysis patients and kid-
ney transplant (KTX) recipients in Taiwan than in other countries. Herein, we 
report a high incidence of urinary tract malignancy, especially TCC, in KTX 
recipients in eastern Taiwan.
Patients and Methods: We retrospectively reviewed the medical records, 
clinical data, and outcomes of 102 KTX recipients in Tzu Chi General 
Hospital from 1992 to 2008. Overall graft and patient survival, incidence of 
posttransplant malignancy, and cumulative incidence of TCC after KTX were 
investigated.
Results: During a mean follow-up of 45.5 ± 38.5 months after KTX, 12 
malignancies were diagnosed in nine recipients. The incidence of post-
transplant malignancy in all recipients was 8.2%. TCC was diagnosed in 
four patients, and all these patients presented with painless gross hema-
turia and hydronephrosis. Three patients had tumor involvement in the 
upper urinary tract. TCC occurred at a mean of 56 ± 70.7 months after 
KTX, and the cumulative incidence of TCC was 4.7% in the first 3 years 
after transplant. Only one patient with triple cancer died of disseminated 
cholangiocarcinoma of the distal common bile duct during a mean follow-
up of 15.8 ± 9.5 months after surgical treatment of TCC.
Conclusion: KTX recipients are at extremely high risk of TCC in eastern 
Taiwan, with an incidence of 3.9%. The cardinal signs of posttransplant TCC 
are painless gross hematuria and hydronephrosis of the native kidney. 
Careful, timely urological screening in KTX recipients warrants early diagnosis 
and good prognosis after aggressive surgical management. [Tzu Chi Med J 
2009;21(2):118–122]
Article info
Article history:
Received: July 4, 2008
Revised: July 23, 2008
Accepted: August 8, 2008
Keywords:
Kidney transplantation
Posttransplant malignancy
Recipient
Transitional cell carcinoma
 TZU CHI MED J  June 2009  Vol 21  No 2 119
1. Introduction
In the last four decades, hundreds of thousands of 
patients with chronic renal failure have survived be-
cause of dialysis and transplantation—two of the most 
striking medical successes of the past 40 years in 
the management of end-stage renal disease (ESRD). 
Kidney transplantation (KTX) in selected patients can 
not only improve quality of life, but also prolong sur-
vival. However, posttransplant malignancy, one of the 
adverse effects of KTX, has emerged as an important 
prognostic factor. An increased incidence of malignant 
transformation in transplant recipients was recognized 
as early as the 1970s, and this effect was ascribed to 
the administration of immunosuppressive medications 
[1–3]. Skin tumors, followed by lymphoma, are the 
most common malignancies in transplant recipients 
[4]. The malignancy rate in the urinary tract including 
the kidney (parenchyma and collecting sys tem), ure-
ter, bladder and urethra in KTX recipients was rarely 
reported in the early era of KTX [5,6], but in the 1990s, 
a high incidence of up to 18% was reported in north-
ern Europe [7]. Also, a high cumulative incidence of 
transitional cell carcinoma (TCC) that reached 17.5% 
in 10 years after KTX has been demonstrated in Taiwan 
[8]. In the present study, the incidence and type of post-
transplant malignancy, especially urinary tract malig-
nancy, are investigated in KTX recipients.
2. Materials and methods
The medical records of KTX recipients who underwent 
regular follow-up at transplant clinics in Tzu Chi 
General Hospital from May 1992 to March 2008 were 
retrospectively reviewed. Recipients who underwent 
KTX in other institutions and who were referred to our 
hospital for regular follow-up were all included in this 
study. The incidence and type of malignancy were 
assessed. The immunosuppressive regimen for induc-
tion therapy was intravenous methylprednisolone (MP) 
alone, at a dosage of 1000 mg (or 10 mg/kg if body 
weight < 60 kg) before reperfusion of the kidney graft 
intraoperatively. The routine maintenance therapy was 
triplicate immunosuppressive agents including MP or 
prednisolone, calcineurin inhibitors, either cyclosporin 
A (CsA; Neoral®, Novartis, Basel, Switzerland) or tac-
rolimus (TAC; Prograf®, Astellas Fujisawa, Osaka, Japan) 
and mycophenolate mofetil (MMF; Cellcept®, Roche, 
Nutley, NJ, USA). MP was administered intravenously 
on the day of transplantation, at a dose of 200 mg/
day. The dosage was tapered to 20 mg/day within 
7 days and then changed to oral prednisolone 20 mg/
day. The dosage of prednisolone was gradually re-
duced to a maintenance dose of 5 mg/day by the 
fourth month. TAC was also started on the day of 
transplantation, at a dose of 0.1–0.15 mg/kg/day. The 
dosage was adjusted to maintain a blood trough level 
in whole blood of 8–12 ng/mL for 1 or 2 months post-
operatively, and 5–10 ng/mL thereafter. Administra-
tion of CsA was started at a dose of 8–10 mg/kg/day on 
the day of transplantation, and was adjusted to main -
tain a CsA trough level in whole blood of 400–700 ng/
mL for 3 months after transplantation, 200–400 ng/mL 
for another 3 months, and then around 100 ng/mL by 
the seventh month after transplantation. MMF was 
started at a dose of 2000 mg/day immediately after 
transplantation, and was reduced to 1000 mg/day 
1 month after transplantation.
Any episode of acute cellular rejection was first 
treated by pulse therapy with MP 1000 mg (or 10 mg/
kg if body weight < 60 kg) by intravenous injection for 
3–5 days. A monoclonal antibody, muromonab-CD3
(OKT-3; Ortho Biotech Products, L.P., Horsham, PA, 
USA), at a dose of 10–15 mg/kg for 5–7 days, was ad-
ministrated only to those patients whose acute rejec-
tion was confirmed by graft biopsy and were refractory 
to pulse therapy.
Urine examination, renal function tests and trough 
levels of calcineurin inhibitors were examined monthly. 
Routine surveillance of malignancy including tumor 
markers such as carcinoembryonic antigen, carbohy-
drate antigen 19-9, cancer antigen 125, cancer antigen 
15-3, and α-fetoprotein, and imaging studies such as 
chest roentgenography and ultrasonography of the ab-
domen and renal graft, and a skin examination were 
performed annually. Pap smears and mammography 
for female recipients and serum prostate specific an-
tigen for male recipients were also checked annually. 
For all patients with chronic viral hepatitis, serum 
α-fetoprotein and liver ultrasonography were routinely 
examined every 6 months. For early detection of uri-
nary tract malignancies, patients with any persistent 
microscopic hematuria (RBC > 8/HPF) or gross hema-
turia would receive an additional urological examina-
tion to identify the source of the blood. Urine cytology 
and endoscopic examination such as cystoscopy and/
or ureteroscopy were the most frequent modalities 
used for further interpretation. Any sus picious lesion 
under endoscopic examination was biopsied. Once 
de novo malignancy was confirmed by pathological 
examination, computed tomography was performed 
for preoperative staging.
TCC was staged according to the TNM system 
(American Joint Committee on Cancer Staging System, 
6th edition, 2001). In the lower urinary tract, a transure-
thral resection (TUR) of the tumor was performed if the 
clinical stage was T1 or earlier, whereas a radical resec-
tion was done if the pathological examination of the 
TUR tumor showed muscular invasion. Adjuvant chemo-
therapy with bladder instillation of mitomycin C was in-
dicated in patients with superficial TCC after TUR. In the 
upper tract, a radical nephroureterectomy was done if 
urine cytology or biopsy demonstrated malignant cells.
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The graft and patient survival and the cumulative 
incidence of TCC were calculated by Kaplan-Meier es-
timates. The patient and graft survival was calculated 
from the date of the first transplantation to the date of 
graft failure with need for dialysis, patient death, or the 
end of this study. Descriptive statistics were expressed 
as mean ± standard deviation (SD) or a percentage. 
Data were processed and analyzed using SPSS ver-
sion 10.0 (SPSS Inc., Chicago, IL, USA) for Windows.
3. Results
There were 102 KTX recipients, 55 men and 47 
women, with a mean age of 48.5 ± 11.4 years, in-
cluded in this study. The graft and patient survival 
at 1, 3, and 5 years after transplantation were 92.6%, 
89.9% and 78.3%, and 97%, 92.5% and 82.2%, re-
spectively (Fig. 1). At a mean follow-up of 45.5 ± 38.5 
months after KTX, 12 de novo malignancies were 
diagnosed in nine KTX recipients. The incidence of 
malignancy in all KTX recipients was 8.2% (Table 1). 
One patient had double cancers (lung cancer and 
Kaposi’s sarcoma of the intestine) and another devel-
oped three cancers (cholangiocarcinoma of the distal 
common bile duct, TCC of the lower urinary tract, and 
basal cell carcinoma of the skin) during the follow-up 
period. Four of the recipients who developed de novo 
malignancies had TCC, with incidences of 3.9% in all 
KTX recipients and 44.4% in all recipients who de-
veloped malignancy. The mean time to occurrence 
of TCC was 56 ± 70.7 months after transplantation. 
The cumulative incidence of TCC was 4.7% in the 
first 3 years after KTX.
Either microscopic or gross hematuria without pain 
was the first clinical presentation in these four TCC 
patients. Hydronephrosis was also found in three pa-
tients. All TCC patients underwent endoscopic biopsy 
and the pathological examination confirmed the diag-
nosis before definite surgery. One of the three patients 
with upper tract TCC had bilateral lesions pathologi-
cally. All patients with upper tract TCC underwent radi-
cal nephroureterectomy and bladder cuff resection and 
one patient with superficial TCC in the lower tract re-
ceived TUR of the bladder tumor plus intravesical che-
motherapy with mitomycin C. During a mean follow-up 
of 15.8 ± 9.5 months, all grafts and patients survived 
except for one recipient with triple cancer who died of 
disseminated cholangiocarcinoma about 22 months 
after the diagnosis of TCC with a functioning graft.
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Fig. 1 — Overall graft survival was 92.6% at 1 year, 89.9% 
at 3 years and 78.3% at 5 years after kidney transplanta-
tion. The overall patient survival at 1, 3 and 5 years was 
97%, 92.5% and 82.2%, respectively.
Table 1 — Data on de novo malignancy in 102 kidney transplant recipients
 
Gender
  Cancer time Cancer time after  Patient Graft
Age 
(M/F)
 Cancer type since ESRD transplantation Type of surgery survival survival
   (mo) (mo)  (Y/N) (Y/N)
66 F TCC 167 161 Right nephroureterectomy Y Y
38 F Cervical SCC 192 132 Conization Y Y
41 F RCC 115   43 – N N
68 M NPC   48   36 – N N
66 M HCC   49   22 Left hepatectomy Y Y
54 M 1. Lung adenocarcinoma    91     7 Left lung lobectomy  
  2. Intestinal Kaposi’s sarcoma    N N
52 M TCC    91   29 Bilateral Y Y
      nephroureterectomy
68 M 1. Cholangiocarcinoma    51     7 Pancreaticoduodenectomy, N N
  2. TCC    bilateral nephroureterectomy, 
  3. BCC    wide excision of BCC
52 F TCC  111    27 TUR-BT Y Y
F = female; M = male; TCC = transitional cell carcinoma; SCC = squamous cell carcinoma; RCC = renal cell carcinoma; NPC = nasopharyngeal cancer; 
HCC = hepatocellular carcinoma; BCC = basal cell carcinoma; TUR-BT = transurethral resection of bladder tumor; Y = survived; N = did not survive.
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4. Discussion
The overall incidence of de novo malignancy after 
KTX has been reported to be three to 10 times higher 
than in the general population [9–11] and three times 
higher than in hemodialysis patients [12]. In Western 
countries, the most common type of posttransplant 
malignancy was non-melanoma skin cancer and the 
main type of malignancy in the urinary tract was renal 
cell carcinoma (RCC) [13], with an incidence of 4.6% 
in all KTX recipients [14]. On the contrary, in our 
series, the most common type of posttransplant ma-
lignancy was TCC. It occurred in 3.9% of all KTX re-
cipients and 44.4% of all patients with posttransplant 
malignancy. Similar results have been reported from 
a Taiwanese series. Wu et al demonstrated a 4.1% 
overall incidence of TCC in KTX recipients and a 
43.5% incidence in all patients with posttransplant 
malignancy [8]. Similarly, a 3.1% incidence of TCC in 
KTX recipients and a 62.5% incidence in all patients 
with posttransplant malignancy was reported by Wang 
et al [15]. It is interesting that the incidence of TCC 
and RCC in ESRD patients and KTX recipients is some-
what different between Taiwan and neighboring coun-
tries such as Japan. The incidence of urinary tract 
TCC and RCC in patients under maintenance dialysis 
was 0.89% and 0.26% in Taiwan, and 0.1% and 0.61% 
in Japan, respectively [12,16]. In Japan, the incidence 
of RCC in KTX recipients was 3.6% [17]. Both dialysis 
patients and transplant recipients had higher inci-
dences of TCC in Taiwan. Old age, compound anal-
gesics, Chinese herb usage, and underground water 
intake as well as female gender have been consid-
ered risk factors [8]. In the present study in eastern 
Taiwan, the population distribution, dietary habits, 
and medication and genetic components were similar 
to those in other areas of Taiwan. But unlike other 
geographic areas of Taiwan, there is less industrial 
pollution and no reported arsenic contamination of 
groundwater in eastern Taiwan. However, the incidence 
of urinary tract malignancy, especially TCC in kidney 
transplant recipients, was still high. The incidence of 
urinary tract TCC and RCC in patients who had un-
dergone kidney transplantation was 3.9% and 1.0%, 
respec tively, in our study. This indicates that environ-
mental contamination might not be the only factor that 
contributes to the development of these posttrans-
plant malignancies. Other major risk factors for urinary 
tract TCC in KTX recipients such as genetic difference, 
long-term hemodialysis [12,18], and pathophysiology 
from ESRD such as diabetes mellitus, and ingestion 
of analgesics [19,20] or aristolochic acid in Chinese 
herbs [21,22] may still need to be considered in the 
difference in incidence between Taiwan and other 
countries. This needs to be investigated further.
Painless hematuria was the major clinical presenta-
tion in KTX recipients with TCC, as in previous reports 
[8,23]. In addition, hydronephrosis is the main sign if 
the upper urinary tract is involved. Therefore, aggres-
sive intervention such as endoscopic examination 
including cystoscopy and/or ureteroscopy, and wash-
ing cytology is indicated when TCC of the urinary tract 
is suspected. Once TCC is documented, an early bi-
lateral radical nephroureterectomy is suggested be-
cause of the high risk of simultaneous development 
of small urothelial malignancy in the opposite tract, 
which occurs in up to 57.1% of cases, and is difficult 
to detect accurately [23].
5. Conclusion
KTX recipients in eastern Taiwan have a high risk of 
TCC, with an incidence of 3.9%. The cardinal signs of 
TCC in KTX recipient are painless gross hematuria 
and hydronephrosis of the native kidney. Careful, 
timely urological screening of KTX recipients warrants 
an early diagnosis and good prognosis after aggressive 
management.
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